Roche hopes to bolster its capabilities in liver and central nervous system (CNS) disorder gene therapies by turning to Dyno Therapeutics. Roche made a splash with its acquisition of Spark Therapeutics, whose Luxturna (voretigene neparvovec), a gene therapy for an inherited form of vision loss, was the first such therapy to win FDA approval. Dyno, a two-year-old startup based in Cambridge, Massachusetts meanwhile, has never brought a gene therapy to the market, nor does it currently have its own drug…